Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct;83(8):973–979. doi: 10.1054/bjoc.2000.1412

Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology

V Minard 1, O Hartmann 2, M C Peyroulet 1, J Michon 1, C Coze 1, A S Defachelle 1, O Lejars 1, Y Perel 1, C Bergeron 1, P Boutard 1, G Leverger 1, J L Stephan 1, A Thyss 1, P Chastagner 1, G Couillault 1, C Devalck 1, P Lutz 1, F Mechinaud 1, F Millot 1, D Plantaz 1, X Rialland 1, H Rubie 1
PMCID: PMC2363565  PMID: 10993641

Abstract

To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised 21 infants with radiologically detectable bone lesions, Group II 22 patients with an unresectable primary tumour and Group III eight patients with only metaiodobenzylguanidine (MIBG) skeletal uptake. MYCN oncogene content was assayed in 47/51 tumours and found to be amplified in 17 (37%). The 5-year event-free survival (EFS) rate of these 51 infants was 64.1% (± 7.1%). In a univariate analysis, bone lesions, MYCN amplification, urinary vanillylmandelic/homovanillic acid ratio and serum ferritin levels adversely influenced outcome. In the multivariate analysis, radiologically detectable bone lesions were the most powerful unfavourable prognostic indicator: the EFS rate was 27.2% for these infants compared to 90% for infants without bone lesions (P < 0.0001). Our data emphasize the poor prognosis of infants affected by stage 4 NB with bone lesions, especially when associated with MYCN amplification. Given the poor results in this group whatever the treatment, new therapeutic approaches need to be investigated in the future. © 2000 Cancer Research Campaign

Keywords: neuroblastoma, infants, metastasis, MYCN, bone lesions

Full Text

The Full Text of this article is available as a PDF (78.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernstein M. L., Leclerc J. M., Bunin G., Brisson L., Robison L., Shuster J., Byrne T., Gregory D., Hill G., Dougherty G. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol. 1992 Feb;10(2):323–329. doi: 10.1200/JCO.1992.10.2.323. [DOI] [PubMed] [Google Scholar]
  2. Bowman L. C., Castleberry R. P., Cantor A., Joshi V., Cohn S. L., Smith E. I., Yu A., Brodeur G. M., Hayes F. A., Look A. T. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997 Mar 5;89(5):373–380. doi: 10.1093/jnci/89.5.373. [DOI] [PubMed] [Google Scholar]
  3. Brodeur G. M., Azar C., Brother M., Hiemstra J., Kaufman B., Marshall H., Moley J., Nakagawara A., Saylors R., Scavarda N. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992 Sep 15;70(6 Suppl):1685–1694. doi: 10.1002/1097-0142(19920915)70:4+<1685::aid-cncr2820701607>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  5. Carlsen N. L., Schroeder H., Bro P. V., Erichsen G., Hamborg-Pedersen B., Jensen K. B., Nielsen O. H. Neuroblastomas treated at the four major child oncologic clinics in Denmark 1943-1980: an evaluation of 180 cases. Med Pediatr Oncol. 1985;13(4):180–186. doi: 10.1002/mpo.2950130404. [DOI] [PubMed] [Google Scholar]
  6. Castel Sánchez V., Melero Moreno C., García-Miguel García-Rosados P., Navajas Gutiérrez A., Ruiz Jiménez J. I., Navarro Fos S., Garín Valle J. C., Galbe Sada M. Neuroblastoma en niños menores de 1 año. An Esp Pediatr. 1997 Dec;47(6):584–590. [PubMed] [Google Scholar]
  7. Coze C., Hartmann O., Michon J., Frappaz D., Dusol F., Rubie H., Plouvier E., Leverger G., Bordigoni P., Béhar C. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997 Dec;15(12):3433–3440. doi: 10.1200/JCO.1997.15.12.3433. [DOI] [PubMed] [Google Scholar]
  8. De Bernardi B., Pianca C., Boni L., Brisigotti M., Carli M., Bagnulo S., Corciulo P., Mancini A., De Laurentis C., Di Tullio M. T. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer. 1992 Sep 15;70(6):1625–1633. doi: 10.1002/1097-0142(19920915)70:6<1625::aid-cncr2820700631>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  9. DuBois S. G., Kalika Y., Lukens J. N., Brodeur G. M., Seeger R. C., Atkinson J. B., Haase G. M., Black C. T., Perez C., Shimada H. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181–189. doi: 10.1097/00043426-199905000-00005. [DOI] [PubMed] [Google Scholar]
  10. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971 Feb;27(2):374–378. doi: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  11. Frappaz D., Michon J., Hartmann O., Bouffet E., Lejars O., Rubie H., Gentet J. C., Chastagner P., Sariban E., Brugiere L. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol. 1992 Oct;10(10):1592–1601. doi: 10.1200/JCO.1992.10.10.1592. [DOI] [PubMed] [Google Scholar]
  12. Goon H. K., Cohen D. H., Harvey J. G. Review of thoracic neuroblastoma. Aust Paediatr J. 1984 Mar;20(1):17–21. doi: 10.1111/j.1440-1754.1984.tb00030.x. [DOI] [PubMed] [Google Scholar]
  13. Hann H. W., Levy H. M., Evans A. E. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 1980 May;40(5):1411–1413. [PubMed] [Google Scholar]
  14. Labreveux de Cervens C., Hartmann O., Bonnin F., Couanet D., Valteau-Couanet D., Lumbroso J., Behar C., Martelli H., Lemerele J. What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age? Med Pediatr Oncol. 1994;22(2):107–114. doi: 10.1002/mpo.2950220209. [DOI] [PubMed] [Google Scholar]
  15. Lampert F., Christiansen H., Berner F., Terpe H. J., Berthold F. Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. J Neurooncol. 1997 Jan;31(1-2):181–184. doi: 10.1023/a:1005778607661. [DOI] [PubMed] [Google Scholar]
  16. Look A. T., Hayes F. A., Nitschke R., McWilliams N. B., Green A. A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984 Jul 26;311(4):231–235. doi: 10.1056/NEJM198407263110405. [DOI] [PubMed] [Google Scholar]
  17. Look A. T., Hayes F. A., Shuster J. J., Douglass E. C., Castleberry R. P., Bowman L. C., Smith E. I., Brodeur G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581–591. doi: 10.1200/JCO.1991.9.4.581. [DOI] [PubMed] [Google Scholar]
  18. McEwan A. J., Shapiro B., Sisson J. C., Beierwaltes W. H., Ackery D. M. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med. 1985 Apr;15(2):132–153. doi: 10.1016/s0001-2998(85)80022-2. [DOI] [PubMed] [Google Scholar]
  19. Nakagawara A., Ikeda K., Tsuda T., Higashi K. N-myc oncogene amplification and prognostic factors of neuroblastoma in children. J Pediatr Surg. 1987 Oct;22(10):895–898. doi: 10.1016/s0022-3468(87)80583-3. [DOI] [PubMed] [Google Scholar]
  20. Paul S. R., Tarbell N. J., Korf B., Kretschmar C. S., Lavally B., Grier H. E. Stage IV neuroblastoma in infants. Long-term survival. Cancer. 1991 Mar 15;67(6):1493–1497. doi: 10.1002/1097-0142(19910315)67:6<1493::aid-cncr2820670605>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  21. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rubie H., Hartmann O., Michon J., Frappaz D., Coze C., Chastagner P., Baranzelli M. C., Plantaz D., Avet-Loiseau H., Bénard J. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol. 1997 Mar;15(3):1171–1182. doi: 10.1200/JCO.1997.15.3.1171. [DOI] [PubMed] [Google Scholar]
  23. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  24. Shuster J. J., McWilliams N. B., Castleberry R., Nitschke R., Smith E. I., Altshuler G., Kun L., Brodeur G., Joshi V., Vietti T. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol. 1992 Aug;15(4):295–303. doi: 10.1097/00000421-199208000-00004. [DOI] [PubMed] [Google Scholar]
  25. Strother D., Shuster J. J., McWilliams N., Nitschke R., Smith E. I., Joshi V. J., Kun L., Hayes F. A., Castleberry R. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol. 1995 Aug;17(3):254–259. doi: 10.1097/00043426-199508000-00007. [DOI] [PubMed] [Google Scholar]
  26. Zeltzer P. M., Marangos P. J., Evans A. E., Schneider S. L. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer. 1986 Mar 15;57(6):1230–1234. doi: 10.1002/1097-0142(19860315)57:6<1230::aid-cncr2820570628>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES